NO20071579L - 4-Heteroarylmetylsubstituerte ftalazinonderivater - Google Patents
4-Heteroarylmetylsubstituerte ftalazinonderivaterInfo
- Publication number
- NO20071579L NO20071579L NO20071579A NO20071579A NO20071579L NO 20071579 L NO20071579 L NO 20071579L NO 20071579 A NO20071579 A NO 20071579A NO 20071579 A NO20071579 A NO 20071579A NO 20071579 L NO20071579 L NO 20071579L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- crxry
- optionally substituted
- group
- heteroarylmethyl
- Prior art date
Links
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0419072.4A GB0419072D0 (en) | 2004-08-26 | 2004-08-26 | Phthalazinone derivatives |
| US60495604P | 2004-08-27 | 2004-08-27 | |
| PCT/GB2005/003343 WO2006021801A1 (en) | 2004-08-26 | 2005-08-26 | 4-heteroarylmethyl substituted phthalazinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20071579L true NO20071579L (no) | 2007-05-29 |
Family
ID=35219560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071579A NO20071579L (no) | 2004-08-26 | 2007-03-26 | 4-Heteroarylmetylsubstituerte ftalazinonderivater |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1791827A1 (https=) |
| JP (1) | JP2008510783A (https=) |
| KR (1) | KR20070057859A (https=) |
| AU (1) | AU2005276229A1 (https=) |
| BR (1) | BRPI0514632A (https=) |
| CA (1) | CA2577191A1 (https=) |
| IL (1) | IL181408A0 (https=) |
| MX (1) | MX2007002318A (https=) |
| NO (1) | NO20071579L (https=) |
| NZ (1) | NZ553979A (https=) |
| WO (1) | WO2006021801A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| WO2007138355A1 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| JP5603770B2 (ja) | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体拮抗薬およびその使用 |
| GB0716532D0 (en) * | 2007-08-24 | 2007-10-03 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| MX2010002749A (es) * | 2007-09-14 | 2010-06-25 | Astrazeneca Ab | Derivados de ftalazinona. |
| EP2220073B1 (en) | 2007-11-15 | 2014-09-03 | MSD Italia S.r.l. | Pyridazinone derivatives as parp inhibitors |
| UY31603A1 (es) * | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CN102256963B (zh) | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| ES2674275T3 (es) | 2009-12-17 | 2018-06-28 | Centrexion Therapeutics Corporation | Antagonistas del receptor CCR2 y usos de los mismos |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
| WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
| JP2013532683A (ja) | 2010-07-27 | 2013-08-19 | カディラ ヘルスケア リミティド | ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体 |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| KR101242572B1 (ko) * | 2010-10-12 | 2013-03-19 | 한국화학연구원 | 5-환 헤테로 아릴로 치환된 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물 |
| JP5699223B2 (ja) * | 2010-12-02 | 2015-04-08 | シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド | 複素環誘導体、その合成法および医療用途 |
| CA2829123C (en) * | 2011-03-14 | 2016-04-12 | Eternity Bioscience Inc. | Quinazolinediones and their use |
| TWI577693B (zh) * | 2011-05-31 | 2017-04-11 | 江蘇康緣藥業股份有限公司 | 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102964354B (zh) * | 2012-11-16 | 2014-08-13 | 江苏先声药业有限公司 | 一类噻吩并咪唑衍生物及其应用 |
| CN102977040B (zh) * | 2012-11-20 | 2015-06-03 | 浙江工业大学 | 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法 |
| HUE030613T2 (en) | 2012-12-31 | 2017-05-29 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 |
| ES2753386T3 (es) | 2013-03-13 | 2020-04-08 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer |
| CN106146492A (zh) * | 2015-04-17 | 2016-11-23 | 上海汇伦生命科技有限公司 | 杂环并咪唑类化合物、其药物组合物及其制备方法和用途 |
| PT3317270T (pt) | 2015-07-02 | 2020-08-24 | Centrexion Therapeutics Corp | (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona |
| CN105384684B (zh) * | 2015-12-16 | 2018-02-13 | 辽宁工程技术大学 | 一种2‑氰基‑6‑甲基吡啶的制备方法 |
| EP3758695A4 (en) * | 2018-02-28 | 2021-10-06 | The Trustees Of The University Of Pennsylvania | POLY (AD-RIBOSE) -POLYMERASE 1 DEPENDENT CYTOTOXIC AGENTS WITH LOW AFFINITY |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| US20220110936A1 (en) * | 2019-02-02 | 2022-04-14 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| US20230234938A1 (en) | 2020-04-28 | 2023-07-27 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| CA3214298A1 (en) | 2021-04-08 | 2022-10-13 | Swaroop Kumar Venkata Satya VAKKALANKA | Inhibitors of poly(adp-ribose) polymerase |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA882639B (en) * | 1987-05-02 | 1988-09-30 | Asta-Pharma Aktiengesellschaft | New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives |
| DE3813531A1 (de) * | 1987-05-02 | 1988-11-10 | Asta Pharma Ag | Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate |
| CA2205757C (en) * | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| GB0026505D0 (en) * | 2000-10-30 | 2000-12-13 | Kudos Pharm Ltd | Phthalazinone derivatives |
| HU228960B1 (hu) * | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| WO2002090334A1 (en) * | 2001-05-08 | 2002-11-14 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| AU2003211381B9 (en) * | 2002-02-19 | 2009-07-30 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| DE60335359D1 (de) * | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
-
2005
- 2005-08-26 JP JP2007528985A patent/JP2008510783A/ja active Pending
- 2005-08-26 WO PCT/GB2005/003343 patent/WO2006021801A1/en not_active Ceased
- 2005-08-26 CA CA002577191A patent/CA2577191A1/en not_active Abandoned
- 2005-08-26 BR BRPI0514632-1A patent/BRPI0514632A/pt not_active IP Right Cessation
- 2005-08-26 AU AU2005276229A patent/AU2005276229A1/en not_active Abandoned
- 2005-08-26 EP EP05775527A patent/EP1791827A1/en not_active Withdrawn
- 2005-08-26 KR KR1020077006778A patent/KR20070057859A/ko not_active Ceased
- 2005-08-26 NZ NZ553979A patent/NZ553979A/en not_active IP Right Cessation
- 2005-08-26 MX MX2007002318A patent/MX2007002318A/es active IP Right Grant
-
2007
- 2007-02-18 IL IL181408A patent/IL181408A0/en unknown
- 2007-03-26 NO NO20071579A patent/NO20071579L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008510783A (ja) | 2008-04-10 |
| EP1791827A1 (en) | 2007-06-06 |
| CA2577191A1 (en) | 2006-03-02 |
| KR20070057859A (ko) | 2007-06-07 |
| WO2006021801A1 (en) | 2006-03-02 |
| AU2005276229A1 (en) | 2006-03-02 |
| IL181408A0 (en) | 2007-07-04 |
| BRPI0514632A (pt) | 2008-06-17 |
| MX2007002318A (es) | 2007-04-17 |
| NZ553979A (en) | 2009-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071579L (no) | 4-Heteroarylmetylsubstituerte ftalazinonderivater | |
| PT1633724E (pt) | Derivados de ftalazinona | |
| MEP14208A (en) | Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents | |
| TNSN05212A1 (en) | Phthalazinone derivatives | |
| ME01515B (me) | PIRIMIDINSKI DERIVATI ZA TRETMAN ASTME, HOBP, ALERGIJSKOG RINITISA, ALERGIJSKOG KONJUNKTIVITISA, ATOPIČNOG DERMATITISA, RAKA, HEPATITISA B, HEPATITISA C, HIV-a, HPV-a, BAKTERIJSKIH INFEKCIJA I DERMATOZE | |
| EP2041159B8 (en) | Macrocyclic compounds as antiviral agents | |
| EA200870344A1 (ru) | Азотсодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента | |
| TW200833675A (en) | Nicotinamide derivatives | |
| UA102574C2 (ru) | 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы | |
| TW200639169A (en) | Bicyclic heteroaryl derivatives for treating viruses | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| TW200833340A (en) | Imidazo [1, 2-b] pyridazine derivatives | |
| DE602005023015D1 (de) | Indolderivate als viruzide | |
| CY1109808T1 (el) | Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α | |
| NO20075409L (no) | Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater | |
| EA201070839A1 (ru) | Новые производные ацилцианопирролидинов | |
| WO2008006969A3 (fr) | Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| ATE359782T1 (de) | Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten | |
| GEP20146063B (en) | Solid pharmaceutical composition | |
| EA201001087A1 (ru) | Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| WO2011042860A3 (en) | New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria | |
| SG156689A1 (en) | Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate | |
| ATE505462T1 (de) | Neue biologischaktive molekü le | |
| NO20081068L (no) | Kinolinderivater som antibakterielle midler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |